Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia

Hydatidiform Mole Clinical Trial

Official title:

A Randomized Phase III Trial of Weekly Parenteral Methotrexate Versus "Pulsed" Dactinomycin as Primary Management for Low Risk Gestational Trophoblastic Neoplasia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00003702
• Other study ID #: GOG-0174
• Secondary ID: NCI-2011-02026EC
• Status: Completed
• Phase: Phase 3
• Start date: June 1999

Study information

• Verified date: February 2016
• Source: Gynecologic Oncology Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Randomized phase III trial to compare the effectiveness of methotrexate with that of dactinomycin in treating patients who have gestational trophoblastic neoplasia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether methotrexate is more effective than dactinomycin in treating patients with gestational trophoblastic neoplasia.

Description:

OBJECTIVES:

I. Compare the efficacy of methotrexate vs dactinomycin, as measured by complete response rate, in patients with low-risk gestational trophoblastic neoplasia.

II. Compare the toxicity of these regimens in these patients. III. Determine whether the definition of persistent gestational trophoblastic neoplasia is accurate (as determined by the likelihood that the beta human chorionic gonadotropin [HCG] titer would decline on the day treatment is initiated).

OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive methotrexate intramuscularly once weekly in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive dactinomycin IV over 15 minutes every 2 weeks in the absence of disease progression or unacceptable toxicity. All patients continue on treatment until 1 beta human chorionic gonadotropin (HCG) titer is below the institutional normal. Patients then receive 1 additional consolidation treatment.

Patients are followed every 4 weeks for 1 year.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 240
• Est. primary completion date: July 2010
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Histologically proven low-risk gestational trophoblastic neoplasia (persistent hydatidiform mole or choriocarcinoma), defined as 1 of the following:

• Less than 10% decrease in the beta human chorionic gonadotropin (HCG) titer over 3 weekly titers

• Greater than 20% sustained rise in beta HCG titer over two consecutive weeks

• Persistently elevated beta HCG titer more than 4 months after initial curettage (greater than 5 mIU/mL minimum)

• Histologically proven nonmetastatic choriocarcinoma

• Metastases to vagina, parametria, or lung (if no single pulmonary lesion is greater than 2 cm)

• WHO score 0-6 (not including blood group or CT lung)

• No histologically confirmed placental site pseudotumor

• Must have undergone at least 1 uterine curettage

• Previously untreated disease

• Performance status - GOG 0-2

• WBC at least 3,000/mm^3

• Granulocyte count at least 1,500/mm^3

• Platelet count at least 100,000/mm^3

• Bilirubin no greater than 1.5 times upper limit of normal (ULN)

• SGPT and SGOT no greater than 3 times ULN

• Alkaline phosphatase no greater than 3 times ULN

• No significant prior abnormal hepatic function

• Creatinine no greater than 2.0 mg/dL

• No significant prior abnormal renal function

• Not pregnant or nursing

• Fertile patients must use effective contraception during and for one year after study entry

• No other prior or concurrent malignancies within the past 5 years except nonmelanomatous skin cancer

• No prior chemotherapy for gestational trophoblastic neoplasia

• No concurrent curettage except as needed to control vaginal bleeding or to rule out placental site pseudotumor

Related Conditions & MeSH terms

• Choriocarcinoma
• Gestational Trophoblastic Disease
• Good Prognosis Metastatic Gestational Trophoblastic Tumor
• Hydatidiform Mole
• Non-Metastatic Gestational Trophoblastic Tumor
• Trophoblastic Neoplasms
• Uterine Corpus Choriocarcinoma

Intervention

Biological:
• Dactinomycin
Given IV

Drug:
• Methotrexate
Given intramuscularly

Locations

Country	Name	City	State
United States	Gynecologic Oncology Group	Philadelphia	Pennsylvania

Sponsors (3)

Lead Sponsor	Collaborator
Gynecologic Oncology Group	Eastern Cooperative Oncology Group, National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response Based on Blood Human Chorionic Gonadotropin (hCG) Assay	Primary outcome is measured as a difference in proportion responding between treatment arms and evaluated using a chi square test. A complete response was defined as a normal hCG sustained over four weekly measurements.	Endpoint was assessed by hCG measurements taken weekly, once normal, treatment was bi-weekly, then monthly, up to 12 months.
Primary	Incidence of Adverse Effects (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 2.0	Number of participants with a maximum grade of 3 or higher during the treatment period.	Prior to study entry, weekly during treatment, up to 12 months after normal titer, an average of 7 months.
Secondary	Number of Patients With a Decline of hCG on Day 1 of Treatment	Number of patients with a decline in hCG on day 1 of treatment relative to the level at enrollment. A decline is defined as a decrease by 1 or more units between enrollment and treatment start.	Prior to study entry and on Day 1 of treatment